AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.57

Change

+0.11 (+3.18)%

Market Cap

USD 0.31B

Volume

0.17M

Avg Analyst Target

USD 11.50 (+222.13%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AUTL Stock Forecast & Price:
Based on the Autolus Therapeutics Ltd stock forecasts from 2 analysts, the average analyst target price for Autolus Therapeutics Ltd is USD 11.50 over the next 12 months. Autolus Therapeutics Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Autolus Therapeutics Ltd is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Autolus Therapeutics Ltd’s stock price was USD 3.57. Autolus Therapeutics Ltd’s stock price has changed by +2.59% over the past week, +19.40% over the past month and -41.57% over the last year.

About Autolus Therapeutics Ltd (AUTL:NSD)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase ...Read More

Company Website : https://www.autolus.com

Address : The MediaWorks, London, United Kingdom, W12 7FP

Employees : 324

Fiscal Year End : September

Currency: USD

Country : USA

Technical Indicators

Beta : 1.39

52 Week High : 7.90

Short Ratio : 9.94

52 Week Low : 1.96

Shorted Shares : 1,308,977

200 Day Moving Average : 4.10

Shorted Shares Previous Month : 1,421,776

50 Day Moving Average : 2.78

Shares Held By Insiders : 16.08%

Short Percentage : 3.62%

Shares Held by Institutions : 58.99%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+2.36 (+0.81%)

 USD74.93B 24.21 16.33
REGN Regeneron Pharmaceuticals Inc

+4.81 (+0.77%)

 USD69.21B 12.88 9.34
MRNA Moderna Inc

-0.63 (-0.37%)

 USD68.17B 5.42 4.08
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.76 (+1.11%)

 USD38.32B 3.09 2.08
SGEN Seagen Inc

-3.90 (-2.24%)

 USD32.10B 55.02 -46.75
RPRX Royalty Pharma Plc

+0.50 (+1.14%)

 USD29.54B 42.84 20.93
ALNY Alnylam Pharmaceuticals Inc

+4.46 (+1.94%)

 USD27.16B N/A -34.32
GMAB Genmab AS

-0.69 (-1.83%)

 USD23.25B 72.63 6.37
ARGX argenx NV ADR

+2.77 (+0.74%)

 USD20.75B N/A -20.02

ETFs Containing AUTL

Symbol Name Weight Mer Price(Change) Market Cap
HOML UBS ETRACS Monthly Reset .. 8.77 % 0.85 %

N/A

 USD2.82M
NAIL Direxion Daily Homebuilde.. 2.05 % 0.96 %

+1.75 (+4.49%)

 USD0.17B
HOMZ The Hoya Capital Housing .. 1.52 % 0.30 %

+0.65 (+1.75%)

 USD0.04B
ZEUS:CA BMO Shiller Select US Ind.. 1.40 % 0.73 %

N/A

 USD9.21M
FXD First Trust Consumer Disc.. 0.00 % 0.61 %

+0.61 (+1.19%)

 USD0.40B
XHB SPDR® S&P Homebuilders E.. 0.00 % 0.35 %

+1.24 (+1.89%)

 USD1.15B
SDVY First Trust SMID Cap Risi.. 0.00 % 0.60 %

+0.40 (+1.47%)

 USD0.92B
FOVL iShares Focused Value Fac.. 0.00 % 0.25 %

+0.53 (+0.99%)

 USD0.03B
DFAT Dimensional U.S. Targeted.. 0.00 % 0.29 %

+0.73 (+1.60%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.21% 55% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.21% 55% F 34% F
Trailing 12 Months  
Capital Gain -39.59% 63% D 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.59% 63% D 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -30.94% 11% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.94% 11% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 28.53% 90% A- 58% F
Risk Adjusted Return -108.43% 4% F 1% F
Market Capitalization 0.31B 61% D- 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.17 69% D+ 70% C-
Price / Cash Flow Ratio -2.61 46% F 63% D
EV/EBITDA -0.40 41% F 60% D-
Management Effectiveness  
Return on Equity -62.13% 47% F 20% F
Return on Invested Capital -53.67% 50% F 19% F
Return on Assets -34.06% 34% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.94 17% F 11% F
Short Percent 3.62% 53% F 42% F
Beta 1.39 43% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector